BRISBANE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devasting inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 2023 Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 10:30 a.m. GMT in London.
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company utilizing a distinct scientific approach to stop C1q and all inflammatory aspects of classical complement pathway activation before it starts. As the only company solely focused on shutting down C1q, Annexon is developing a fit-for-purpose pipeline of therapeutics designed to provide meaningful benefits across multiple diseases of the body, brain and eye. With proof-of concept data in both Guillain-Barré syndrome and geographic atrophy, Annexon is rigorously advancing its mid-to late-stage clinical trials to bring their potential treatments to patients as quickly as possible. To learn more visit www.annexonbio.com.
Investor Contact:
Chelcie Lister
THRUST Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Sheryl Seapy
Real Chemistry
949-903-4750
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.15 |
| Daily Change: | -0.02 -0.39 |
| Daily Volume: | 117,234 |
| Market Cap: | US$543.570M |
November 14, 2024 October 15, 2024 September 09, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
